Blood filter targets DNA to tame septic shock inflammation
NCT ID NCT07657767
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a device called Nucleocore that removes cell-free DNA (cfDNA) from the blood of people with septic shock. High cfDNA levels are linked to severe inflammation and worse outcomes. The study enrolls adults aged 18-65 with septic shock and elevated cfDNA, and measures whether filtering the blood can reduce shock duration and improve recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Efferon CT plasma adsorption column (Nucleocore)
What this could lead to
If it works, this could provide a new way to treat septic shock by filtering out harmful DNA fragments that drive inflammation.
What could go wrong
This is an early-stage trial with only 60 participants, so results may not apply to all septic shock patients. The procedure carries risks from vascular access and blood filtering.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moscow City Clinical Hospital named after S. S. Yudin
Moscow, Russia